Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 7,667 call options on the company. This is an increase of approximately 58% compared to the typical daily volume of 4,843 call options.

Analysts Set New Price Targets

RXRX has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, November 7th. Jefferies Financial Group decreased their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $9.25.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $6.27, for a total value of $71,772.69. Following the sale, the director now directly owns 7,121,322 shares in the company, valued at $44,650,688.94. The trade was a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 171,682 shares of company stock valued at $1,133,471. 15.75% of the stock is currently owned by corporate insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently made changes to their positions in RXRX. Geode Capital Management LLC raised its stake in Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after acquiring an additional 656,003 shares during the period. Barclays PLC increased its holdings in shares of Recursion Pharmaceuticals by 53.9% in the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock valued at $4,596,000 after purchasing an additional 244,278 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Recursion Pharmaceuticals in the third quarter valued at about $692,000. State Street Corp lifted its stake in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of Recursion Pharmaceuticals by 48.8% during the 3rd quarter. Stifel Financial Corp now owns 161,978 shares of the company’s stock worth $1,067,000 after buying an additional 53,103 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Down 3.5 %

RXRX traded down $0.22 during trading on Wednesday, reaching $6.05. 3,623,033 shares of the stock were exchanged, compared to its average volume of 5,779,855. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock’s 50 day moving average price is $6.66 and its two-hundred day moving average price is $7.55. Recursion Pharmaceuticals has a twelve month low of $5.84 and a twelve month high of $15.74. The stock has a market cap of $1.73 billion, a P/E ratio of -4.10 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. The firm’s revenue for the quarter was up 147.6% on a year-over-year basis. Equities analysts expect that Recursion Pharmaceuticals will post -1.56 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.